ArticlePloS one2024
Clinical efficacy analysis of the Chinese medicine Paiteling applied to human papillomavirus infection: A retrospective study.
Article in PloS one, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Clinical application of modified Yihuang Decoction for the treatment of cervical high-risk HPV persistent infection.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Article
- The co-regulation of HPV infection by vaginal microbiota and the immune system.Virology journal · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimTo investigate the clinical efficacy of population-based treatment of human papillomavirus (HPV) infections with Paiteling.
methodsBetween 1 June 2024 and 31 August 2024, 575 HPV-infected patients attending The First People's Hospital of Jingzhou gynecology outpatient clinic from October 2020 to December 2023 were retrospectively collected, all of whom were analyzed for HPV subtype infection and the presence or absence of cytomorphological abnormality using HPV-DNA testing and TCT; they were divided into 319 cases in the Paiteling group and 256 cases in the Interferon group, and the patients of both groups were subjected to TCT 1 month after the end of the administration of the medication and HPV review.
results1. The three most frequent subtypes of HPV in this data are HPV 16, HPV 52, and HPV 58, all of which are high-risk types; 2. The results of the post-treatment review of HPV infection showed that the overall effective rate of the Paiteling group was better than that of the Interferon group, and the difference in the cumulative effective rate between the two groups was statistically significant (P < 0.001); 3. Comparative analysis of patients with 14 high-risk types of human papillomavirus in a single infection showed that the overall conversion rate in the Paiteling group was 76.3%, higher than that of the Interferon group, which was 36.7%. The difference was statistically significant (P < 0.001).
conclusionThe overall efficacy of Paiteling for cervical HPV infection is significantly better than that of Interferon, and it is worth promoting its use in the clinic.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.